Tortoise Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Tortoise Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10	Closed	-$3.92K	–	1421
2025 Q3	$3.92K	Buy	10 +6	+150%	+$2.51K	﹤0.01%	738
2025 Q2	$1.78K	Buy	+4	New	+$1.84K	﹤0.01%	830
2024 Q1	–	Sell	-5	Closed	-$2.03K	–	889
2023 Q4	$2.03K	Hold	5	–	–	﹤0.01%	707
2023 Q3	$1.74K	Buy	+5	New	+$1.75K	﹤0.01%	713
2020 Q2	–	Sell	-28	Closed	-$7K	–	558
2020 Q1	$7K	Hold	28	–	–	﹤0.01%	414
2019 Q4	$6K	Hold	28	–	–	﹤0.01%	473
2019 Q3	$5K	Hold	28	–	–	﹤0.01%	479
2019 Q2	$5K	Hold	28	–	–	﹤0.01%	504
2019 Q1	$5K	Buy	+28	New	+$5.17K	﹤0.01%	490
2013 Q4	–	Sell	-40	Closed	-$3K	–	384
2013 Q3	$3K	Hold	40	–	–	﹤0.01%	290
2013 Q2	$3K	Buy	+40	New	+$2.95K	﹤0.01%	316

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Tortoise Investment Management's VRTX Position: Q4 2025 in Review

Tortoise Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 10 shares — an estimated $3.92K sold.

Tortoise Investment Management first reported a position in VRTX in Q2 2013 and held it in 11 quarters. The position peaked at $7K in Q1 2020. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

Tortoise Investment Management reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Tortoise Investment Management sold 10 Vertex Pharmaceuticals shares in Q4 2025, an estimated $3.92K.
Tortoise Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 11 quarters.
Tortoise Investment Management's Vertex Pharmaceuticals position peaked at $7K in Q1 2020.
1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Tortoise Investment Management's 13F filing for Q4 2025, filed 6 Feb 2026.